Your session is about to expire
What is Lenvima
LenvatinibThe Generic name of this drug
Treatment SummaryLenvatinib is a medication used to treat thyroid cancer that does not respond to radioactive iodine (RAI). It works by blocking the activity of certain proteins that regulate cell growth and division, including vascular endothelial growth factor (VEGF) receptors and other receptors found in the cell membrane. These proteins are involved in the development of abnormal blood vessels, tumors, and cancer progression, and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib has been approved by the FDA for the treatment of patients with locally recurrent or metastatic, progressive, RAI-refractory differentiated
Lenvimais the brand name
Lenvima Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lenvima
Lenvatinib
2015
8
Approved as Treatment by the FDA
Lenvatinib, also known as Lenvima, is approved by the FDA for 6 uses like Advanced Renal Cell Carcinoma (aRCC) and previous anti-angiogenic therapy .Advanced Renal Cell Carcinoma (aRCC)
Used to treat Advanced Renal Cell Carcinoma (aRCC) in combination with Everolimus
previous anti-angiogenic therapy
Used to treat previous anti-angiogenic therapy in combination with Everolimus
Endometrial Carcinoma
Used to treat Endometrial Carcinoma in combination with Pembrolizumab
Mismatch Repair-deficient (dMMR)
Used to treat Mismatch Repair-deficient (dMMR) in combination with Pembrolizumab
Microsatellite Instability High
Used to treat Microsatellite Instability High in combination with Pembrolizumab
Disease
Used to treat disease progression after previous treatment in combination with Pembrolizumab
Effectiveness
How Lenvima Affects PatientsLenvatinib works by blocking a protein called VEGFR2, which helps regulate certain signals in the body. By blocking this protein, lenvatinib is able to reduce the activity of certain signaling pathways.
How Lenvima works in the bodyLenvatinib is a type of medication that limits the growth of tumors. It does this by blocking the action of certain proteins, called receptor tyrosine kinases, which are involved in the formation of new blood vessels and in the growth of tumors. Lenvatinib blocks the activity of VEGF receptors, FGF receptors, PDGFRα, KIT, and RET proteins.
When to interrupt dosage
The endorsed dosage of Lenvima is contingent upon the indicated condition, including Malignant Neoplasms, progressive radioactive iodine-refractory Thyroid cancer and Malignant Neoplasms. The quantity of dosage shifts as per the technique of delivery featured in the following table.Condition
Dosage
Administration
Unresectable Hepatocellular Carcinoma (HCC)
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Mismatch Repair-deficient (dMMR)
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Disease
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
previous anti-angiogenic therapy
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Microsatellite Instability High
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Endometrial Carcinoma
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Advanced Renal Cell Carcinoma (aRCC)
10.0 mg, , 14.0 mg, 4.0 mg, 12.0 mg/dose, 14.0 mg/dose, 18.0 mg/dose, 24.0 mg/dose, 4.0 mg/dose, 10.0 mg/dose, 8.0 mg/dose, 20.0 mg/dose
, Capsule - Oral, Oral, Capsule
Warnings
There are 20 known major drug interactions with Lenvima.Common Lenvima Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Amiodarone.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Asenapine.
Lenvima Toxicity & Overdose RiskTaking lenvatinib can lead to high blood pressure, diarrhea, fatigue, decreased appetite, weight loss, nausea, mouth sores, tingling in the hands or feet, and increased protein in the urine. Other potential side effects include heart or blood vessel problems, liver damage, kidney damage, a hole in the digestive tract, irregular heartbeat, low calcium levels, brain damage, excessive bleeding, and decreased effectiveness of the thyroid. Women who are pregnant or of reproductive age should use contraception while taking lenvatinib and for 2 weeks after treatment ends.
Lenvima Novel Uses: Which Conditions Have a Clinical Trial Featuring Lenvima?
Fifteen active clinical trials are being conducted to analyze the potential of Lenvima to treat Malignant Neoplasms, Advanced Renal Cell Carcinoma (aRCC) and Progressive Radioactive Iodine-Refractory Thyroid Cancer.Condition
Clinical Trials
Trial Phases
Endometrial Carcinoma
23 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1
Advanced Renal Cell Carcinoma (aRCC)
17 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2
Disease
0 Actively Recruiting
Microsatellite Instability High
4 Actively Recruiting
Phase 1, Phase 2
previous anti-angiogenic therapy
0 Actively Recruiting
Mismatch Repair-deficient (dMMR)
7 Actively Recruiting
Phase 2, Phase 1
Unresectable Hepatocellular Carcinoma (HCC)
14 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Lenvima Reviews: What are patients saying about Lenvima?
5Patient Review
8/11/2018 I've been taking Lenvima for almost two and a half years now. It's kept my tumor from growing, and even shrunk it by 50%. The main downside is that I get diarrhea quite often, but it's worth it to me since the alternative is letting the cancer grow unchecked.
5Patient Review
6/16/2015 This drug has been working great for me. The only downside is that my blood pressure has increased, but the tumors I have either decreased in size or stayed the same.
5Patient Review
6/11/2022 I started at 24mg and experienced really bad pain and stomach problems. I decreased the dosage to 10mg, which is more tolerable, but I still have issues with bloating, nausea, constipation, and diarrhea. The good news is that my scans show that the tumors are stable and not growing or spreading.
3.7Patient Review
8/3/2018 I've suffered from some nasty side effects since starting this medication. My blood pressure spikes as soon as I take it, and I have to take blood pressure medication alongside the lenvatinib. I also get mouth sores, a thick tongue, loss of appetite, severe fatigue, and no quality of life. I've been hospitalized three times in the past year due to dehydration and infections. Coconut water helps with the nausea and dehydration somewhat, but overall this has been a tough experience.
3.3Patient Review
6/1/2022 I've been on this treatment for two months now, and while it initially caused my blood pressure to skyrocket, I decreased the dose and have been feeling better since. However, I have experienced some unpleasant side effects, like a metal taste in my mouth and bad cramps in both thighs. I'm calcium supplementing in hopes of alleviating some of these issues. Only time will tell if this treatment is effective against my tumors.
3Patient Review
3/7/2020 I experienced fatigue, nosebleeds, feet pain, and other flu-like symptoms while taking this medication.
1Patient Review
12/13/2019 I was hospitalized three times within three months of taking Lenvima. I experienced a lot of side effects and had to get a feeding tube. I also had to have a tracheostomy procedure because of fistula development in my trachea. I took the full dosage, 24 mg, but it did not improve my quality of life at all. Now my only option is radiation.
1Patient Review
1/9/2019 My father took Lenvima and contracted septic shock. He passed away 9 days later.
Patient Q&A Section about lenvima
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Lenvima?
"The text is discussing the side effects of the drug LENVIMA. The most common side effects include fatigue, joint and muscle pain, decreased appetite, weight loss, nausea, mouth sores, headache, vomiting, and skin rashes. Additionally, some people may experience abdominal pain and hoarseness."
Answered by AI
What does the drug Lenvima do?
"LENVIMA is a kinase inhibitor.
LENVIMA is a prescription medication used to treat different types of cancer, including differentiated thyroid cancer (DTC). DTC is a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing. LENVIMA is a kinase inhibitor."
Answered by AI